• LAST PRICE
    2.6300
  • TODAY'S CHANGE (%)
    Trending Down-0.0400 (-1.4981%)
  • Bid / Lots
    2.4600/ 30
  • Ask / Lots
    2.7400/ 25
  • Open / Previous Close
    2.6500 / 2.6700
  • Day Range
    Low 2.6000
    High 2.7000
  • 52 Week Range
    Low 2.0400
    High 17.4846
  • Volume
    40,536
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 2.67
TimeVolumeTALS
09:32 ET5592.65
09:38 ET5002.66
09:39 ET6002.65
10:06 ET1002.69
10:10 ET1002.6191
11:18 ET1002.7
12:56 ET8002.66
02:02 ET1072.63
02:31 ET16002.635
02:33 ET1802.635
02:42 ET3002.635
03:02 ET11792.61
03:03 ET3002.61
03:05 ET10502.61
03:07 ET1002.61
03:14 ET1002.61
03:41 ET4002.625
03:50 ET1002.64
03:52 ET1002.64
03:54 ET1002.625
03:56 ET35002.61
03:57 ET7122.635
03:59 ET193322.63
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesTALS
Talaris Therapeutics Inc
102.6M
-1.7x
---
United StatesALZN
Alzamend Neuro Inc
105.0M
-8.4x
---
United StatesENZC
Enzolytics Inc
97.1M
-0.3x
---
United StatesATOS
Atossa Therapeutics Inc
103.8M
-4.9x
---
United StatesIMUX
Immunic Inc
91.7M
-1.1x
---
United StatesINZY
Inozyme Pharma Inc
103.6M
-1.1x
---
As of 2022-10-02

Company Information

Talaris Therapeutics, Inc. is a late-clinical stage, cell therapy company developing therapies. The Company is principally focused on developing allogeneic hematopoietic stem cell transplantation (allo-HSCT). The Company's lead product candidate, FCR001, which is central to its facilitated Allo-HSCT therapy, is an allogeneic cell therapy comprised of stem and immune cells that are procured from a healthy donor. FCR001 is processed in the Company's good manufacturing practice (GMP) facility using proprietary manufacturing methods. The Company's clinical programs include FREEDOM-1, FREEDOM-2 and FREEDOM-3. It is advancing a pipeline of programs across three therapeutic categories: solid organ transplantation, severe autoimmune disease, and severe non-malignant blood, immune and metabolic disorders.

Contact Information

Headquarters
570 Preston St., Suite 400LOUISVILLE, KY, United States 40202
Phone
502-398-9250
Fax
302-636-5454

Executives

Independent Chairman of the Board
Francois Nader
President, Chief Executive Officer, Director
Scott Requadt
Chief Financial Officer, Treasurer
Mary Fenton
Chief Technology Officer
Michael Zdanowski
Chief Scientific Officer, Director
Suzanne Ildstad

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$102.6M
Revenue (TTM)
$0.00
Shares Outstanding
41.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-1.55
Book Value
$5.93
P/E Ratio
-1.7x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.